Trial reportBlood2020
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.
2 registry-linked trialsAbstract readLetterRandomized Controlled Trial
In one paragraph
Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 90 papers.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine
NCT05710783 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation
Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2
Who cites it
90 citing papers in PubMed.
- SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors.European journal of internal medicine · 2021Trial
- Differential immune profiles in elderly patients with non-severe versus severe SARS-CoV-2 omicron variant infection: dysregulation of antibody responses and B-cell subsets.Immunity & ageing : I & A · 2025Article
- Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.Virology · 2025Article
- Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform.medRxiv : the preprint server for health sciences · 2024Article
- Canada's approach to SARS-CoV-2 sero-surveillance: Lessons learned for routine surveillance and future pandemics.Canadian journal of public health = Revue canadienne de sante publique · 2024Article
- Frequency of SARS-CoV-2 Infections among Healthcare Workers in Germany: 3-Year Follow-Up Study.Infectious disease reports · 2024Article
- Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.iScience · 2024Article
- Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.Scientific reports · 2024Article
- Article
- Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV).BMJ open · 2023Article
- Quantification of Severe Acute Respiratory Syndrome Coronavirus 2 Binding Antibody Levels To Assess Infection and Vaccine-Induced Immunity Using WHO Standards.Microbiology spectrum · 2023Article
- Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection.Medical microbiology and immunology · 2023Article
- Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination.Vaccines · 2023Article
- The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice.Cell reports. Medicine · 2023Article
- Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection.Irish journal of medical science · 2022Article
- Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance.Clinics in laboratory medicine · 2022Review
- An implementation of a hybrid method based on machine learning to identify biomarkers in the Covid-19 diagnosis using DNA sequences.Chemometrics and intelligent laboratory systems : an international journal sponsored by the Chemometrics Society · 2022Article
- Assessment of the levels of antispike SARS-CoV-2 IgG antibodies and their association with clinical characteristics in cohort of patients in Saudi Arabia.Journal of family medicine and primary care · 2022Article
- Article
- Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Josée PerreaultHéma-Québec, Affaires Médicales et Innovation, Québec, QC, Canada.
Tony TremblayHéma-Québec, Affaires Médicales et Innovation, Québec, QC, Canada.
Marie-Josée FournierHéma-Québec, Affaires Médicales et Innovation, Québec, QC, Canada.
Mathieu DrouinHéma-Québec, Affaires Médicales et Innovation, Québec, QC, Canada.
Guillaume Beaudoin-BussièresCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Jérémie PrévostCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Antoine LewinHéma-Québec, Affaires Médicales et Innovation, Montréal, QC, Canada.
Philippe BéginCentre de Recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada; and.
Andrés FinziCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Renée BazinHéma-Québec, Affaires Médicales et Innovation, Québec, QC, Canada.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Seroepidemiologic StudiesAdultAgedAntibodies, NeutralizingAntibodies, ViralCOVID-19FemaleHumansLongitudinal StudiesMaleMiddle AgedSARS-CoV-2Tissue DonorsYoung AdultAntibodies, NeutralizingAntibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05205746ClinicalTrials.gov
NCT05710783ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.